FDA publishes post CRL guidance for generic companies

4 December 2018
drugs_pills_tablets_big

The US Food and Drug Administration (FDA) has published final guidance for the generics industry on post-complete response letter (CRL) meetings.

Such meetings take place between the FDA and generic drug companies to clarify deficiencies identified in a CRL to an abbreviated new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The FDA has revised the draft guidance on this matter to provide clarifying information on the process for submitting post-CRL meeting requests and the criteria for granting such requests.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics